Gilead Sciences stock nears its all-time high
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...